Toggle light / dark theme

Discovery of an antibody that stimulates the immune system to eliminate cancer cells

Major work led by Dr. André Veillette’s team at the Institut de recherches cliniques de Montréal (IRCM), in collaboration with a group of researchers, and just published in Nature Immunology, managed to identify a previously unknown molecular action that prevents phagocytosis, which is a process that promotes the immune system’s response to cancer. A Research Briefing on the work done by the team has been published in the same journal.

Macrophages are cells of the immune system. One of the roles of is to engulf, or “eat,” cells that are defective or dangerous, including cancer cells. This process is named phagocytosis. Macrophages can be called into action to eliminate cancer cells. However, this capacity is often defective, because macrophages are put in a state of dormancy by the cancer cells.

This is in part because a particular molecule called CD47 is often over-abundant on cancer cells. CD47 prevents phagocytosis by triggering a molecule or “receptor” on macrophages named SIRPα. Agents that block the ability of CD47 to trigger SIRPα have shown promising results for treating cancer.

New study reveals the critical role of microglia in human brain development

The researchers used human stem cells to create a model of early brain development — organoids.


Super-resolution image of human stem cell-derived Microglia cells with labeled mitochondria (yellow), nucleus (magenta), and actin filaments (cyan). These Microglia cells help in the maturation of neurons in human brain organoid models. Photo credit: A*STAR’s SIgN

An international team of scientists has uncovered the vital role of microglia, the immune cells in the brain that acts as its dedicated defense team, in early human brain development.

The world’s first gene therapy for sickle cell disease has been approved in Britain

LONDON (AP) — Britain’s medicines regulator has authorized the world’s first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. In a statement Thursday, the Medicines and Healthcare Regulatory Agency said it approved Casgevy, the first medicine licensed using the gene editing tool CRISPR, which won its makers a Nobel prize in 2020. The agency approved…

Wearable device harnesses body sounds for continuous health monitoring

The devices demonstrated clinical-grade accuracy and introduced novel functionalities not seen in prior research or clinical care.


Northwestern University.

Furthering the scope of such examinations, a team of researchers at Northwestern University (NU) is now presenting novel wearable technology much more advanced than the intermittent measures made during periodic medical examinations.

Putin Wants Russia to Win the Artificial Intelligence Race. Here’s Why it Won’t

“Whoever leads in AI will rule the world,” President Vladimir Putin declared at an address commencing the 2017 Russian school year. Six years later, despite intense focus from senior leadership and heavy investment from the federal budget and state-owned enterprises, Russia remains a laggard in this field, hobbled by international isolation and structural challenges.

Military, political, and business leaders in Moscow have long understood the importance of controlling the information space to secure their grasp on power. After the scare of social media powered “color revolutions” on Russia’s doorstep, Moscow doubled down on these efforts. But facing both headwinds intrinsic to the nature of generative AI and deep, self-inflicted wounds from the war in Ukraine, the window for Russia to take a lead is closing quickly.

Russia’s leaders were caught flat-footed by the rise of social media. The supposed dangers of emerging technology were brought to the fore by Chisinau’s so-called “ Twitter revolution,” when protests organized in part on American social networks prevented Moldova’s ardently pro-Russian Party of Communists from winning the election in 2009.

U.K. Greenlights World’s First Crispr Gene Editing Therapy

The one-time treatment helped relieve symptoms of disease and could free patients from the need for bone marrow transplants or regular blood transfusions, Beach said, adding that the drug hopefully offers a permanent fix for the condition.

The MHRA said it identified no significant safety concerns during the trials and will continue to closely monitor Casgevy’s safety after approval.

Vertex CEO and President Reshma Kewalramanit celebrated Casgevy’s approval as “a historic day in science and medicine” and Samarth Kulkarni, CEO and Chairman of Crispr Therapeutics, said it will hopefully mark “the first of many applications of this Nobel Prize winning technology to benefit eligible patients with serious diseases.” The two companies are hoping for similarly positive decisions from the MHRA’s counterparts in the Europe Union and the U.S., which are in the process of evaluating Casgevy, also known as exa-cel. The Food and Drug Administration is expected to make a decision in early December and has a deadline of December 8. The agency appears poised to follow the MHRA and approve the treatment, with its advisors confident of the drug’s efficacy and benefit but wary of theoretical unintended consequences of genetic modifications.

Hackers Could Exploit Google Workspace and Cloud Platform for Ransomware Attacks

A set of novel attack methods has been demonstrated against Google Workspace and the Google Cloud Platform that could be potentially leveraged by threat actors to conduct ransomware, data exfiltration, and password recovery attacks.

“Starting from a single compromised machine, threat actors could progress in several ways: they could move to other cloned machines with GCPW installed, gain access to the cloud platform with custom permissions, or decrypt locally stored passwords to continue their attack beyond the Google ecosystem,” Martin Zugec, technical solutions director at Bitdefender, said in a new report.

A prerequisite for these attacks is that the bad actor has already gained access to a local machine through other means, prompting Google to mark the bug as not eligible for fixing “since it’s outside of our threat model and the behavior is in line with Chrome’s practices of storing local data.”

/* */